Voyager Therapeutics Quick Ratio 2014-2022 | VYGR

Historical quick ratio values for Voyager Therapeutics (VYGR) over the last 10 years.
Voyager Therapeutics Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-03-31 $0.00B $0.10B 0.00
2021-12-31 $0.00B $0.05B 0.00
2021-09-30 $0.00B $0.03B 0.00
2021-06-30 $0.00B $0.03B 0.00
2021-03-31 $0.00B $0.03B 0.00
2020-12-31 $0.00B $0.03B 0.00
2020-09-30 $0.00B $0.04B 0.00
2020-06-30 $0.00B $0.07B 0.00
2020-03-31 $0.00B $0.07B 0.00
2019-12-31 $0.00B $0.08B 0.00
2019-09-30 $0.00B $0.08B 0.00
2019-06-30 $0.00B $0.07B 0.00
2019-03-31 $0.00B $0.06B 0.00
2018-12-31 $0.00B $0.03B 0.00
2018-09-30 $0.00B $0.03B 0.00
2018-06-30 $0.00B $0.03B 0.00
2018-03-31 $0.00B $0.03B 0.00
2017-12-31 $0.00B $0.02B 0.00
2017-09-30 $0.00B $0.02B 0.00
2017-06-30 $0.00B $0.01B 0.00
2017-03-31 $0.00B $0.01B 0.00
2016-12-31 $0.00B $0.01B 0.00
2016-09-30 $0.00B $0.02B 0.00
2016-06-30 $0.00B $0.02B 0.00
2016-03-31 $0.00B $0.02B 0.00
2015-12-31 $0.00B $0.02B 0.00
2015-09-30 $0.00B $0.02B 0.00
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B $0.00B 0.00
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.227B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00